Publications
8 shownFive-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advance...
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint i...
Cancer immunotherapy using checkpoint blockade
The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses i...
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Adverse eve...
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Immune checkpoint inhibitors, which unleash a patient’s own T cells to kill tumors, are revolutionizing cancer treatment. To unravel the genomic determinants of response to this...
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rat...
Frequent Co-Authors
Researcher Info
- h-index
- 8
- Publications
- 8
- Citations
- 44,797
- Institution
- Cornell University
External Links
Identifiers
- ORCID
- 0000-0001-6718-2222
Impact Metrics
h-index: Number of publications with at least h citations each.